Stockreport

enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference [Yahoo! Finance]

enGene Holdings Inc.  (ENGN) 
PDF pivotal results and a targeted BLA filing in H2 2026 aiming for approval in 2027, and the company reports more than $300 million in cash runway into late 2028. Detalim [Read more]